期刊文献+

恶性肿瘤风险指数在卵巢恶性肿瘤诊断中的价值 被引量:5

下载PDF
导出
摘要 目的探讨血清癌抗原125(CA125)、超声分数、绝经状态以及恶性肿瘤风险指数在卵巢肿瘤早期诊断中的应用,探讨卵巢恶性肿瘤术前检测方法及临床意义。方法选取安徽省立医院收治卵巢肿瘤患者1695例,年龄介于14~78岁之间,所有患者均为首次治疗,术后均进行病理诊断,分别以其术前血清CA125、超声评分、绝经状态和恶性肿瘤风险指数(RMI)值,对卵巢良恶性进行预测,比较其敏感性、特异性、阳性预测值、阴性预测值。结果以CA125>35判断卵巢恶性肿瘤的敏感性及特异性为81.95%,71.97%。以绝经为界其敏感性及特异性为70.05%,64.65%。以B超>2分为界其敏感性及特异性为64.75%,97.36%。以RMI>200为界其敏感性、特异性分别为64.55%,95.51%。结论RMI较CA125、超声评分、绝经状态具有较好的准确性,在临床上具有较大的应用价值。
出处 《中国临床保健杂志》 CAS 2016年第2期141-143,共3页 Chinese Journal of Clinical Healthcare
  • 相关文献

参考文献10

  • 1Siegel R ,N aishadham D ,Jem al A . C ancer s ta tis tic s,2012[ J ] . C A Cancer J C lin ,2 0 1 2 ,6 2 ( 1 ): 10-29.
  • 2Hennessy BT,Coleman RL,MarAman M. Ovarian cancer [J]. Lancet,2009,374(9698) :1371-1382.
  • 3Vergote I,Trope CG,Amant F,et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovariancancer[ J]. N Engl J Med ,2010,363 ( 10) : 943-953.
  • 4Tingulstad, Hagen B, Skjeldestad FE, et al. The risk of malignancy index to evaluate po tential ovarian cancers in local hospitals[ J]. Br J Obstet Gy necol, 1999,93 ( 3 ): 448.
  • 5Jacobs I ,Oram D,Fairbanks J,et al. A risk of malignancy index in corpo rating CA125, ultrasound and menopausal status fo r the accurate preoperative diag nosis of ovarian cancer [ J ]. Br J Obstet Gynecol, 1990,97 ( 10 ): 922.
  • 6崔恒,谢幸.正确认识和应用肿瘤标记物[J].中国妇产科临床杂志,2011,12(5):321-323. 被引量:6
  • 7Drapkin R,von Horsten HH,Lin Y,et al. Human epididymis protein 4 ( HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcino- mas[J]. Cancer Res,2005,65(6) :2162 - 2169.
  • 8Moore RG,Brown AK,Miller MC,et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass [ J ]. Gynecol Oncol ,2008 ,108 ( 2) :402^08.
  • 9Hasanbegovic L, Alicelebic S, Sljivo N. Comparison of specific ovarian tumor markers by elecsys analyzer 2010 [J]. Acta Inform Med,2015 ,23(2) :86-89.
  • 10Van Gorp T,Veldman J,Van Calster B,et al. Subjective assessment by ultrasound is superior to the risk of malig-nancy index (RMI) or the risk of ovarian malignancy al-gorithm (ROMA) in discriminating benign from malignant adnexal masses [ J ]. Eur J Cancer, 2012,48 ( 11 ).

二级参考文献8

  • 1Rustin GJ, van den Burg M. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 levels alone versus delayed treatment based on conventional clinical indicators (MRC OV5/EORTC 55955 trials). J Clin Oncol, 2009, 27: 1.
  • 2Aggarwal P, Kehoe S. Serum turnnur markers in gynaecological cancers. Maturitas, 2010, 67: 46-53.
  • 3Anderson GL, Mclntosh M, Wu LL, et al. Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study. J Natl Cancer Inst, 2010, 102:26 - 38.
  • 4Demirtas E, Krishnamurthy S, Tulandi T. Elevated serum beta--human chorionic gonadotropin in nonpregnant conditions. Obstet Gynecol Surv, 2007, 62: 675-679.
  • 5Cole LA, Butler SA. Hyperglyeosylated human chorionic gonadotropin and human chorionie gonadotropin free beta-suhunit: tumor markers and tumor promoters. J Reprod Med, 2008, 53:499-512.
  • 6Iles RK. Ectopic hCG beta expression by epithelial cancer: malignant behaviour, metastasis and inhibition of tumor cell apoptosis. Mol Cell Endocrinol, 2007, 260 - 262,264 - 270.
  • 7Cole LA. Hyperglycosylated hCG, a review. Placenta, 2010, 31: 653- 664.
  • 8卢仁泉,郭林,沈烨红.HE4在卵巢癌诊治中的临床应用评价[J].中国癌症杂志,2010,20(9):680-685. 被引量:39

共引文献5

同被引文献32

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部